Guanglei Z. Chen

Shenyang, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 49 publications

Supramolecular polymers with water-triggered dense domains enabling mechanical robustness programmability and weather resistance.

Supramolecular polymers with water-triggered dense domains enabling mechanical robustness programmability and weather resistance.

Journal: Nature communications

Published: December 08, 2025

Correction: Association of human breast cancer CD44-/CD24- cells with delayed distant metastasis.

Correction: Association of human breast cancer CD44-/CD24- cells with delayed distant metastasis.

Journal: eLife

Published: September 10, 2025

Efficacy and safety of neoadjuvant stereotactic body radiation therapy plus dalpiciclib and exemestane for hormone receptor-positive, HER2-negative breast cancer: A prospective pilot study.

Efficacy and safety of neoadjuvant stereotactic body radiation therapy plus dalpiciclib and exemestane for hormone receptor-positive, HER2-negative breast cancer: A prospective pilot study.

Journal: eLife

Published: July 28, 2025

Correction: Binding blockade between TLN1 and integrin β1 represses triple-negative breast cancer.

Correction: Binding blockade between TLN1 and integrin β1 represses triple-negative breast cancer.

Journal: eLife

Published: May 08, 2025

Correction: Targeting SOST using a small‑molecule compound retards breast cancer bone metastasis.

Correction: Targeting SOST using a small‑molecule compound retards breast cancer bone metastasis.

Journal: Molecular cancer

Published: April 16, 2025

Correction: CMTM6 overexpression confers trastuzumab resistance in HER2‑positive breast cancer.

Correction: CMTM6 overexpression confers trastuzumab resistance in HER2‑positive breast cancer.

Journal: Molecular cancer

Published: April 14, 2025

Erratum to: FSIP1 enhances the therapeutic sensitivity to CDK4/6 inhibitors in triple-negative breast cancer patients by activating the Nanog pathway.

Erratum to: FSIP1 enhances the therapeutic sensitivity to CDK4/6 inhibitors in triple-negative breast cancer patients by activating the Nanog pathway.

Journal: Science China. Life sciences

Published: March 18, 2025

Neoadjuvant ARX788 plus pyrotinib versus trastuzumab, pertuzumab, docetaxel and carboplatin for HER2-positive breast cancer: a randomised phase 2b trial.

Neoadjuvant ARX788 plus pyrotinib versus trastuzumab, pertuzumab, docetaxel and carboplatin for HER2-positive breast cancer: a randomised phase 2b trial.

Journal: Nature communications

Published: February 19, 2025

Neoadjuvant chidamide combined with chemotherapy in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (MUKDEN 05): a multicentre, single-arm, phase 2 trial.

Neoadjuvant chidamide combined with chemotherapy in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (MUKDEN 05): a multicentre, single-arm, phase 2 trial.

Journal: The Lancet regional health. Western Pacific

Published: January 30, 2025

Advancements in liquid biopsy for breast Cancer: Molecular biomarkers and clinical applications.

Advancements in liquid biopsy for breast Cancer: Molecular biomarkers and clinical applications.

Journal: Cancer treatment reviews

Published: January 26, 2025

Surgical and Oncologic Outcomes of Tumescence and Sharp Dissection Versus Electrocautery Dissection in Minimal-Access Nipple-Sparing Mastectomy with Immediate Prosthesis Breast Reconstruction: A Real-World Retrospective Cohort Study.

Surgical and Oncologic Outcomes of Tumescence and Sharp Dissection Versus Electrocautery Dissection in Minimal-Access Nipple-Sparing Mastectomy with Immediate Prosthesis Breast Reconstruction: A Real-World Retrospective Cohort Study.

Journal: Annals of surgical oncology

Published: December 11, 2024

BD-StableNet: a deep stable learning model with an automatic lesion area detection function for predicting malignancy in BI-RADS category 3-4A lesions.

BD-StableNet: a deep stable learning model with an automatic lesion area detection function for predicting malignancy in BI-RADS category 3-4A lesions.

Journal: Physics in medicine and biology

Published: June 26, 2024

Showing 1-12 of 49

Last Updated: 09/26/2026